Hi Jerrio, I'll add that zero value has been attributed to the Alere deal over the past three year R&D collaboration and is still assigning zero value now that a licensing deal has been signed.  I mean if we figure this test will hit the market in 1-2 years max and it will be worth 10's of millions to MOM then a discounted cash flow should give us a NPV.  Because we have no timeline for introduction, no idea what the milestone payments or royalties will be this part of their business has been discounted to zero.  Heck, we are not even properly valued for PreVu let alone Endoglin.